Subsequent analyses on the interactions between tumor cells and CD8+ effector T cells saw that the CCL chemotaxis signaling, major histocompatibility complex-I antigen presentation signaling, and IFN-II/TNF tumor killing signaling were all reduced in RAC1A159V tumors (Fig. 3G). The gene discussed is CD8A; the disease is neoplasm.